what glp 1 How GLP-1 medications are transforming diabetes and weight loss treatment GLP-1 Updates for Employers: Demand,

GLP-1 Receptor Agonists [review]

60 Risk factors for experiencing DKA with SGLT2-I are not fully understood but may include type 1 diabetes, treatment with insulin, volume depletion, alcohol use, illness, and those in postoperative status

Emerging evidence was found assessing the GLP-1 RAs liraglutide, semaglutide, and tirzepatide and the effects on associated IIH symptoms (Table 3)

[DOI] [PMC free article] [PubMed] [Google Scholar] 189.Fan H., Gong N., Li T.F., Ma A.N., Wu X.Y., Wang M.W

This study confirms no association between GLP-1 RAs and cancer development

It is reasonable to take both observations seriously as hypotheses, with two cautions: Phase 2 trials are smaller, and the trial populations are not identical to GLP-1 trial populations